Bronchial Neoplasms  >>  Mekinist (trametinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mekinist (trametinib) / Novartis, BeiGene
NCT01362296: An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Checkmark WCLC 2013
Oct 2013 - Oct 2013: WCLC 2013
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
134
US, Europe, RoW
GSK1120212, docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
09/12
09/13
NCT02672358: Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Withdrawn
2
0
NA
Dabrafenib, Trametinib
Novartis Pharmaceuticals
Non-Small-Cell Lung Cancer
09/19
12/20
NCT02580708: Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Terminated
1/2
7
US
Rociletinib, CO-1686, Trametinib, Mekinist
Clovis Oncology, Inc., Novartis Pharmaceuticals
Non-small Cell Lung Cancer
05/16
06/16

Download Options